Innovative chemo-genomic tools to improve clinical outcome in acute myeloid leukemia

Principal Investigator: Guy Sauvageau, Josée Hébert
Theme : Health
Competition : Genomics and Personalized Health
Status : Completed
Start : Apr. 1, 2013
End: Mar. 31, 2017
Budget : $11,325,631.00

More accurate prognostic test for better management of patients with acute myeloid leukemia

Acute myeloid leukemia is a particularly lethal form of cancer, with most patients dying within two years of diagnosis. It is one of the leading causes of death among young adults. Existing prognostic tests are often inaccurate, leaving doctors with no tools to guide their decision making about treatment options. 

The project will help increase the survival rate of patients with acute myeloid leukemia by helping to determine treatment based on the genetic makeup of their leukemia cells. By giving hemato-oncologists access to more accurate tools, this project will help pave the way for a new era in personalized medicine and offer patients better targeted therapies. It can also help avoid unnecessary hospitalizations and treatments, while generating significant savings in health care expenditures – a potential sum of $34 million annually.


Co-applicants and End-users:

Denise Avard

McGill University

Frédéric Barabé

CHU de Québec

Michel Bouvier

IRIC, Université de Montréal

Sébastien Lemieux

IRIC, Université de Montréal

Anne Marinier

IRIC, Université de Montréal

Alenjandro Murua

Université de Montréal

Brian Whilhem

Université de Montréal

Ma’n Zawati

McGill University

Julie Bergeron

Hôpital Maisonneuve-Rosemont

Kathy Chun

North York General Hospital

Michelle le Beau

University of Chicago, USA

Brian Leber

McMaster University

 Samir Taga 

Hôpital Maisonneuve-Rosemont

Richard Van der Jagt

The Ottawa Hospital

Agnes V. Klein

Health Canada